Laughing Water Capital’s New Position: Theravance Biopharma (TBPH)
Laughing Water Capital, an investment management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here.
Theravance Biopharma Inc. (TBPH)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Madison Avenue Partners Eli Samaha | 9,212,252 | $156,608,284 | -4% | 6.74% |
| 2. | Weiss Asset Management Andrew Weiss | 7,457,060 | $126,770,020 | 1.33% | |
| 3. | Newtyn Management Noah Levy And Eugene Dozortsev | 3,434,191 | $58,381,247 | -30% | 7.29% |
| 4. | Irenic Capital Management Adam Katz And Andy Dodge | 2,760,948 | $46,936,116 | 2.25% | |
| 5. | D E Shaw D. E. Shaw | 1,185,390 | $20,151,630 | +25% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.80 | 999,800 | $7,798,440.00 | 9,511,150 | 2024-08-07 | Filing | |
| $8.75 | 499,324 | $4,369,085.00 | 8,511,350 | 2024-05-01 | Filing | |
| $8.75 | 999,800 | $8,748,250.00 | 8,012,026 | 2024-05-01 | Filing | |
| $22.54 | 1,000 | $22,540.00 | 56,757 | 2018-05-21 | Filing | |
| $26.34 | 4,000 | $105,358.80 | 213,180 | 2017-08-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.03 | 6,657 | $113,396.67 | 213,476 | 2026-09-15 | Filing | |
| $17.03 | 3,328 | $56,690.15 | 220,133 | 2026-09-15 | Filing | |
| $17.03 | 3,329 | $56,706.52 | 223,461 | 2026-09-15 | Filing | |
| $17.17 | 5,564 | $95,540.56 | 9,167,489 | 2026-07-07 | Filing | |
| $17.04 | 1,400 | $23,856.00 | 9,173,053 | 2026-07-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,562,487 | $77,562,279 | 0% | |
| 2. | 1,771,493 | $30,115,381 | 0% | |
| 3. | 1,328,584 | $22,585,928 | 0% | |
| 4. | 1,117,895 | $19,006,198 | 0% | |
| 5. | 1,043,051 | $17,732,125 | 0% |
News See All
B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14
Theravance Biopharma, Inc. (NASDAQ:TBPH) is one of the most undervalued biotech stocks to buy right now. B. Riley lifted the price target on Theravance Biopharma, Inc.
8 Most Undervalued Biotech Stocks to Buy Right Now
In this article, we will look at the 8 Most Undervalued Biotech Stocks to Buy Right Now.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2025 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2025 Earnings Call Transcript November 10, 2025Theravance Biopharma, Inc. beats earnings expectations. Reported EPS is $0.07, expectations were $-0.03.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call Transcript August 12, 2025Theravance Biopharma, Inc. beats earnings expectations. Reported EPS is $1.08, expectations were $-0.14.
Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma
Viatris Inc. (NASDAQ:VTRS) is one of the best low priced pharma stocks to buy now.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call Transcript May 8, 2025 Operator: Hello, ladies and gentlemen. Good afternoon.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript February 26, 2025Theravance Biopharma, Inc. misses on earnings expectations.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, good afternoon.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2024 Earnings Call Transcript August 5, 2024Theravance Biopharma, Inc. misses on earnings expectations.
Hedge Fund Resource Center